161P - Long-term survival in adults suffered from malignant mesothelioma and pulmonary tuberculosis combined - observational study

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Mesothelioma
Cancer in Special Situations
Presenter Barbara Rybacka-Chabros
Citation Annals of Oncology (2015) 26 (suppl_1): 48-50. 10.1093/annonc/mdv052
Authors B.U. Rybacka-Chabros1, A. Oszywa-Chabros2, J. Milanowski1
  • 1Department Of Pulmonology Allergology And Oncology, Medical University of Lublin, 20-950 - Lublin/PL
  • 2Department Of Endocrynology, Medical University of Lublin, 20-950 - Lublin/PL

Abstract

Aim/Background

The aim of the study was epidemiological comparative analysis of overall survival in adults diagnosed with malignant mesothelioma and pulmonary tuberculosis combined and those who suffered from malignant mesothelioma alone.

Methods

We analyzed 19 patients (12 male and 7 female) aged 51 - 70 yrs hospitalized in our clinic between 2000 and 2013. This study group consists of patients with inoperable malignant mesothelioma alone (11 cases) and patients with coexistence of inoperable malignant mesothelioma and active pulmonary tuberculosis (8 cases). All patients underwent the proper chemotherapy, such as cisplatin or carboplatin and pemetrexed combined or pemetrexed alone. In 7 cases subsequent radiotherapy was conducted. Eight patients with active pulmonary tuberculosis received anti-tuberculosis drugs additionally as concomitant medication. In each study subject clinical perfomace status according to ECOG scale was 2 or less. Spiral computed tomography was performed as diagnostic procedure and after each 2 months during therapy.

Results

In 11 patients with unresectable malignant mesothelioma alone, who received chemotherapy or chemotherapy and radiotherapy combined, progression free survival (PFS) was ranged from 2 to 5 months and the overall survival (OS) was ranged from 6 to 13 months. In 8 patients with coexistance of inoperable malignant mesothelioma and active pulmonary tuberculosis - progression free survival (PFS) was ranged from 5 to 11 months, and overall survival (OS) was ranged from 18 to 24 months. The frequency of drug-dependent side effects was similar in both study groups.

Conclusions

The results of our observational study showed significantly longer overall survival and progression free survival in patients with coexistence of inoperable malignant mesothelioma and active pulmonary tuberculosis to compare patients with inoperable mesothelioma malignium alone. This epidemiological data remains a stimulus for authors to continue clinical investigations in this field.

Disclosure

All authors have declared no conflicts of interest.